Per capsule: Active ingredient: Umifenovir hydrochloride monohydrate (in terms of Umifenovir hydrochloride) - 200 mg. Excipients: potato starch - 52.67 mg, microcrystalline cellulose - 11.20 mg, colloidal silicon dioxide (Aerosil) - 2.80 mg, povidone (Collidone 25) - 7.73 mg, calcium stearate - 2.80 mg, croscarmellose sodium - 2.80 mg; capsule mass - 280 mg. Hard gelatin capsules No. 0: Composition of the capsule shell (body and cap): titanium dioxide (E 171) - 1.92 mg, gelatin - 94.08 mg. The total weight of the capsule is 376 mg.
Specifically inhibits in vitro influenza A and B viruses (Influenzavirus A, B),
including the highly pathogenic subtypes A (H1N1) pdm09 and A (H5N1), as well as other viruses - ARVI pathogens (Coronavirus) associated with severe acute respiratory syndrome (SARS),
respiratory syncytial virus (Pneumovirus) and parainfluenza virus (Paramyxovirus)).
According to the mechanism of antiviral action, it belongs to fusion (fusion) inhibitors, interacts with the hemagglutinin of the virus and prevents the fusion of the lipid membrane of the virus and cell membranes. It has a moderate immunomodulatory effect, increases the body's resistance to viral infections.
It has interferon-inducing activity - in a study on mice, the induction of interferons was observed after 16 hours, and high titers of interferons remained in the blood up to 48 hours after administration.
Stimulates cellular and humoral immunity reactions: increases the number of lymphocytes in the blood, especially T-cells (CD3), increases the number of T-helpers (CD4), without affecting the level of T-suppressors (CD8), normalizes the immunoregulatory index, stimulates the phagocytic function of macrophages and increases the number of natural killer cells (NK cells).
Therapeutic efficacy in viral infections is manifested in a decrease in the duration and severity of the course of the disease and its main symptoms, as well as in a decrease in the frequency of development of complications associated with a viral infection and exacerbations of chronic bacterial diseases. Refers to low-toxic drugs (LD50> 4 g / kg).
It does not have any negative effects on the human body when administered orally in recommended doses.
It is rapidly absorbed and distributed to organs and tissues.
The maximum concentration in blood plasma when taken at a dose of 50 mg is reached after 1.2 hours, at a dose of 100 mg - after 1.5 hours. It is metabolized in the liver.
The half-life is 17-21 hours. About 40% is excreted unchanged, mainly with bile (38.9%) and in a small amount by the kidneys (0.12%). During the first day, 90% of the administered dose is excreted.
children from 12 years: influenza A and B, other acute respiratory viral infections (including complicated by bronchitis, pneumonia), severe acute respiratory syndrome (SARS);
Combined therapy of acute intestinal infections of rotavirus etiology in children over 12 years old. Combined therapy of chronic bronchitis, pneumonia and recurrent herpetic infection. Prevention of postoperative infectious complications.
Hypersensitivity to the drug, age up to 12 years. Pregnancy and lactation: Animal studies have not revealed harmful effects on pregnancy, the development of the embryo and fetus, labor and postnatal development.
The use of the drug Arbidol® Maximum in the first trimester of pregnancy is contraindicated. In the second and third trimester of pregnancy, Arbidol® Maximum can only be used for the treatment and prevention of influenza, and if the intended benefit to the mother outweighs the potential risk to the fetus. The benefit / risk ratio is determined by the attending physician. It is not known whether Arbidol® Maximum passes into breast milk in women during lactation. If necessary, use Arbidol® Maximum should stop breastfeeding.
When prescribed with other drugs, no negative effects were noted
Inside, before eating. A single dose for adults and children over 12 years of age is 200 mg (1 capsule). For non-specific prophylaxis and treatment of influenza and other acute respiratory viral infections: Non-specific prophylaxis of influenza and other acute respiratory viral infections: - For non-specific prophylaxis during the epidemic of influenza and other acute respiratory viral infections: 200 mg (1 capsule) 2 times a week for 3 weeks. - in direct contact with patients with influenza and other acute respiratory viral infections: 200 mg (1 capsule) once a day for 10-14 days. Treatment of influenza and other acute respiratory viral infections: - in uncomplicated course: 200 mg (1 capsule) 4 times a day (every 6 hours) for 5 days. - with the development of complications (bronchitis, pneumonia, etc.): 200 mg (1 capsule) 4 times a day (every 6 hours) for 5 days, then a single dose 1 time per week for 4 weeks. Combined therapy of acute intestinal infections of rotavirus etiology in children over 12 years of age: - 200 mg (1 capsule) 4 times a day (every 6 hours) for 5 days. For non-specific prophylaxis and treatment of severe acute respiratory syndrome (SARS):
For non-specific prevention of SARS (in contact with the patient): - 200 mg (1 capsule) once a day for 12-14 days. For the treatment of SARS: 200 mg (1 capsule) 2 times a day for 8-10 days. In the complex treatment of chronic bronchitis, pneumonia and herpetic infection: - 200 mg (1 capsule) 4 times a day (every 6 hours) for 5-7 days, then a single dose 2 times a week for 4 weeks.
Prevention of postoperative complications: - 200 mg (1 capsule) 2 days before surgery, then 2 and 5 days after surgery.
Overdose Not marked.
|Pills in 1 package||10|
|Expiration Date (in months)||24|
|Country of origin||Russia|